5.90

3.96% 0.225

Eyepoint Pharmaceuticals Inc (EYPT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Eyepoint Pharmaceuticals Inc stock is traded at $5.90, with a volume of 510.54K. It is up +3.96% in the last 24 hours and down -5.60% over the past month. EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Previous Close:

$5.675

Open:

$5.56

24h Volume:

510.54K

Relative Volume:

0.62

Market Cap:

$392.44M

Revenue:

$46.02M

Net Income/Loss:

$-70.80M

P/E Ratio:

-3.2418

EPS:

-1.82

Net Cash Flow:

$-1.61M

1W Performance:

+3.33%

1M Performance:

-5.60%

6M Performance:

-44.86%

1Y Performance:

-66.57%

1-Day Range:

$5.44

$6.14

1-Week Range:

$5.37

$6.14

52-Week Range:

$3.91

$21.25

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name

Eyepoint Pharmaceuticals Inc

Sector

Healthcare (1155)

Industry

Biotechnology (677)

Phone

617-926-5000

Address

480 PLEASANT STREET, WATERTOWN, MA

Employee

144

Twitter

@eyepointpharma

Next Earnings Date

2025-03-05

Latest SEC Filings

EYPT's Discussions on Twitter

Compare EYPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EYPT Eyepoint Pharmaceuticals Inc	5.90	392.44M	46.02M	-70.80M	-1.61M	-1.82
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-25	Initiated	Citigroup	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy
Jan-22-24	Initiated	JP Morgan	Overweight
Nov-02-23	Initiated	Mizuho	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Jul-07-22	Initiated	Chardan Capital Markets	Buy
Mar-01-21	Initiated	Cowen	Outperform
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral
Nov-04-19	Resumed	Laidlaw	Buy
Sep-12-19	Initiated	Guggenheim	Buy

View All

Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News

Apr 16, 2025

Pars Planitis Market Set to Grow Substantially Through 2032, - openPR.com

Apr 16, 2025

EyePoint (EYPT) Offers Stock Options as Inducement for New Hires | EYPT Stock News - GuruFocus

Apr 16, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EYPT Stock News - GuruFocus

Apr 16, 2025

Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com

Apr 16, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Apr 16, 2025

EyePoint Expands Team with Strategic Stock Options Package Worth $370K - Stock Titan

Apr 16, 2025

How the (EYPT) price action is used to our Advantage - news.stocktradersdaily.com

Apr 16, 2025

Apr 09, 2025

Nano Silicon Drug Delivery Platform Market to Witness Massive - openPR.com

Apr 09, 2025

Apr 06, 2025

Ex-Dividend Date Nearing for These 10 Stocks – Week of April 7, 2025 - The Globe and Mail

Apr 06, 2025

Apr 05, 2025

EyePoint Pharmaceuticals' US$84m Market Cap Fall Books Insider Losses - simplywall.st

Apr 05, 2025

Apr 04, 2025

EyePoint Pharmaceuticals at RBC Conference: Insights on Duravu’s Promise By Investing.com - Investing.com Canada

Apr 04, 2025

Apr 03, 2025

Working At Eyepoint - EyePoint Pharmaceuticals

Apr 03, 2025

Apr 02, 2025

Here's Why We're Watching EyePoint Pharmaceuticals' (NASDAQ:EYPT) Cash Burn Situation - Yahoo Finance

Apr 02, 2025

Mar 30, 2025

Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com

Mar 30, 2025

Mar 28, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World

Mar 28, 2025

Mar 27, 2025

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times

Mar 27, 2025

EyePoint's CEO Takes Center Stage: Key Updates Coming at RBC Ophthalmology Conference - Stock Titan

Mar 27, 2025

What is Chardan Capital’s Estimate for EYPT FY2026 Earnings? - Defense World

Mar 27, 2025

Mar 23, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 23, 2025

Mar 21, 2025

3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets

Mar 21, 2025

Mar 20, 2025

(EYPT) Investment Report - news.stocktradersdaily.com

Mar 20, 2025

Mar 19, 2025

Mizuho maintains EyePoint stock Outperform with $30 target By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Mizuho maintains EyePoint stock Outperform with $30 target - Investing.com India

Mar 18, 2025

Mar 14, 2025

Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India

Mar 14, 2025

StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to “Sell” - Defense World

Mar 14, 2025

Mar 12, 2025

EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada

Mar 12, 2025

Mar 10, 2025

Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World

Mar 10, 2025

Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World

Mar 10, 2025

Mar 09, 2025